Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endo To Launch Opana ER Oxymorphone With Two Risk Management Programs

This article was originally published in The Pink Sheet Daily

Executive Summary

The firm will add 220 sales reps to support the July launch of the extended-release and immediate-release opioid analgesics.

You may also be interested in...



Endo Gains Phase II Oral Mucositis Agent With RxKinetix Acquisition

Agreement is in line with Endo’s strategy of expanding into therapeutic areas complementary to pain.

Endo Gains Phase II Oral Mucositis Agent With RxKinetix Acquisition

Agreement is in line with Endo’s strategy of expanding into therapeutic areas complementary to pain.

Opana Uptake Slower Than Anticipated, But Script Growth Is On The Rise

Scripts for Endo's oral oxymorphone reached 1,137 the week of Sept. 29, according to IMS weekly trend data.

Related Content

Topics

UsernamePublicRestriction

Register

PS064381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel